Finerenone Proves Effective in Slowing Kidney Decline for Non-Diabetic Patients
Finerenone slows kidney function decline in non-diabetic patients
Image: Medical News
An international study led by Hiddo Lambers Heerspink reveals that finerenone significantly slows kidney function decline in non-diabetic patients with chronic kidney disease (CKD). The findings suggest a new treatment option for this underserved population, reducing complications and improving kidney health.
- 01The FIND-CKD study involved 1,584 adults with CKD, showing finerenone users had a significantly smaller decline in kidney function compared to those on placebo.
- 02Finerenone reduced the risk of serious kidney problems and cardiovascular events by approximately 23%.
- 03Patients taking finerenone experienced a 41% average decrease in protein levels in urine, an indicator of kidney damage.
- 04The drug is effective for a significant portion of CKD patients who do not have diabetes, expanding treatment options for this group.
- 05Finerenone has been found to be safe for use, offering a new therapeutic avenue for managing CKD.
Advertisement
In-Article Ad
Finerenone has been shown to significantly slow the decline of kidney function in patients with chronic kidney disease (CKD) who do not have diabetes, according to a study led by Hiddo Lambers Heerspink at the University Medical Center Groningen. The FIND-CKD study, which followed 1,584 adults over an average of three years, demonstrated that patients receiving finerenone experienced a statistically significant lesser decline in kidney function, measured by the estimated glomerular filtration rate (eGFR), compared to those on a placebo. Additionally, finerenone reduced the risk of serious kidney issues, heart failure hospitalizations, and cardiovascular deaths by about 23%. Notably, over 41% of finerenone users showed a decrease in urinary protein levels, indicating improved kidney health. These results are particularly important as they highlight a new treatment option for the over half of CKD patients worldwide who are non-diabetic, a group that has limited therapeutic choices. The findings were published in the New England Journal of Medicine.
Advertisement
In-Article Ad
The findings from the study could significantly improve treatment options for non-diabetic patients with chronic kidney disease, impacting healthcare practices.
Advertisement
In-Article Ad
Reader Poll
Do you think finerenone should be widely adopted for treating non-diabetic CKD patients?
Connecting to poll...
Read the original article
Visit the source for the complete story.